ArticleFrontiers in immunology2022
IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Wogonin attenuates psoriasis through anti-inflammatory effects by inhibiting reactive oxygen species production and the AKT/NF-κB signaling pathway.Scientific reports · 2026Article
- Integrated long-read transcriptomic profiling of peripheral blood from ankylosing spondylitis patients identifies regulatory shifts and core genes associated with programmed cell death.Frontiers in immunology · 2026Article
- Clinical efficacy of 308 nm excimer laser irradiation combined with 0.1% tacrolimus ointment in the treatment of plaque-type psoriasis.Lasers in medical science · 2025Observational
- Cross-sectional study of proteomic differences between moderate and severe psoriasis.Scientific reports · 2025Article
- Scalp seborrheic dermatitis demonstrates a skewing of Th1 activation: a proteomic study in lesional skin.Frontiers in immunology · 2025Article
- Article
- Bilayered skin equivalent mimicking psoriasis as predictive tool for preclinical treatment studies.Communications biology · 2024Article
- Impact of Blood-Count-Derived Inflammatory Markers in Psoriatic Disease Progression.Life (Basel, Switzerland) · 2024Article
- Discovery of PANoptosis-related signatures correlates with immune cell infiltration in psoriasis.PloS one · 2024Article
- Single-cell RNA sequencing highlights the influence of innate and adaptive immune response mechanisms in psoriatic arthritis.Frontiers in immunology · 2024Article
- Risk factors of primary liver cancer initiation associated with tumour initiating cell emergence: novel targets for promising preventive therapies.eGastroenterology · 2023Review
- Impact of Pretreatment Systemic Inflammatory Markers on Treatment Persistence with Biologics and Conventional Systemic Therapy: A Retrospective Study of Patients with Psoriasis Vulgaris and Psoriatic Arthritis.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adalimumab and secukinumab are commonly used for moderate to severe psoriasis vulgaris (PV). Although distinct individual responses to and impaired effectiveness of these biological agents occur occasionally, little is known about the underlying reasons. Here, we report a proteomic analysis of psoriatic lesions from patients treated with these drugs using data-independent acquisition mass spectrometry (DIA-MS). Thousands of differentially expressed proteins (DEPs) changed over 12 weeks of treatment. Network analysis showed that DEPs could interact and induce transformation in matrix components, metabolic regulation, and immune response. The results of parallel reaction monitoring (PRM) analysis suggested that S100s, STAT1, KRT2, TYMP, SOD2, HSP90AB1, TFRC, and COL5A1 were the most significantly changed proteins in both groups. There was a positive association between the Psoriasis Area and Severity Index (PASI) score and three proteins (TFRC, IMPDH2, KRT2). Our study findings suggest that inhibition of IL-17A and TNF-α can induce changes in multiple molecules in psoriatic lesions and have an overlapping influence on the immune response and process through direct or indirect effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.